Navigation Links
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
Date:4/23/2013

Valeant expects to complete the tender offer and consummate the merger promptly after the AMC's approval of the acquisition is received.  Except for the extension of the offer expiration date, all other terms and conditions of the offer remain unchanged. Stockholders who have already tendered their shares of common stock of Obagi do not have to re-tender their shares or take any other action as a result of the extension of the expiration date of the offer.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements
This press release contains forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Obagi, satisfaction of closing conditions and the timing of closing.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect the proposed business combination of the companies and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the acquisition will not close when expected or at all; the risk that Valeant's business and/or Obagi's business will be adversely impacted during t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
2. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
5. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
6. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
7. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
8. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
9. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
10. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
11. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry is ... with a focus on the Chinese situation. Major companies included in the propanol market ... Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides a ...
(Date:7/30/2015)... , July 30, 2015  With over 60,000 customers across the globe, ISN improves ... 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over ... Headquartered in Dallas, TX ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... applications and designed for continuous operation up to 1500 bar. The sanitary design ... efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal ...
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / 20% of ... growth in China , as well as solid contributions from ... Europe / Middle East / ... gains in Germany , Turkey and ... / 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... 16%, net Profit up 17%, - Sound Financial Position, - Proposed Increase in Dividend, , ... EUR millions 2007 ... ... %, ...
... March 24 Stallergenes S.A. and,Solvay Pharmaceuticals Marketing ... signing of an exclusive partnership agreement for the,promotion ... Russia and the Commonwealth of Independent States (CIS). ... 20 million allergy sufferers and a strong demand ...
... 24 Accera, Inc., a biotechnology company delivering breakthrough ... that Thomas Werner, Ph.D. has been elected to its ... managing director and senior vice president of GlaxoSmithKline (GSK) ... until earlier this year. He led the Pharmaceutical Research ...
Cached Biology Technology:STALLERGENES: 2008: Strong Performance 2STALLERGENES: 2008: Strong Performance 3Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 2Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 3Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors 2
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 /PRNewswire/ ... today announced BD & Guidepoint Mentor, a ... access to Guidepoint,s expert network services. ... cutting-edge technologies to improve healthcare delivery and outcomes and, ... each start-up entrepreneur will be able to directly engage ...
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... STATION When Atlantic Richfield Co. was tasked with cleaning ... Dr. Frank Hons, a Texas A&M University professor, got a ... Hons, a soil and crop science professor, spent two years ... impacted by 100 years of copper mining, mineral processing and ...
... world leader in synthetic diamond supermaterials, and academic ... Chemistry and Physics, have demonstrated the key factors ... synthetic diamond. The research shows that boron-doped synthetic ... full strength and durability of its chemical structure. ...
... Technology (Caltech) have been able, for the first time, ... DNA, and to measure the rate at which that ... infection by this type of virusa bacteriophagethe scientists have ... rather than the amount of genetic material within the ...
Cached Biology News:Mining cleanup benefits from Texas A&M expertise 2Mining cleanup benefits from Texas A&M expertise 3Synthetic diamond steps closer to next generation of high performance electrochemical applications 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 3The physics of going viral 2The physics of going viral 3The physics of going viral 4
SHEEP ANTI DEHYDROEPIANDROSTERONE...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure Grade DAPI is greater than or equal to 98% pure by HPLC....
... et.al. (1997) • Contains short ... biochemistry & molecular biology, arranged ... Entries give details of biochemical ... which they are involved and ...
... • This book describes the basic ... preparing samples for protein transfer and ... bioluminescence-enhanced detection systems are also included. ... and characterization of glycoprotein carbohydrate chains ...
Biology Products: